Forte Biosciences, Inc. - Common Stock, par value $0.001 per share (FBRX)

CUSIP: 34962G208

Q2 2026 13F Holders as of 30 Jun 2026

Holder snapshot 7 signals
Share change
+6,642,530
Put/Call ratio
613%
SEC-reported price per share
$21.25
Number of holders
85
Value change
+$139,177,583
Number of buys
60
Open additional details 1 more signal available
Number of sells
31
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
20,402,903

Security key

34962G208

Report period

Q2 2026

Institutions

85

Top holders

10

Ownership snapshot

Top reported holders of FBRX - Forte Biosciences, Inc. - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
FEDERATED HERMES, INC.
Disclosed value leader
ORBIMED ADVISORS LLC
Comparable rows
15/15
Latest evidence
30 Jun 2026
13F 13D/G Lead comparable stake: 10% 13D/G row: FEDERATED HERMES, INC. Showing 1-6 of 15 holder rows.

Quick read

FEDERATED HERMES, INC. leads the comparable SEC ownership view at 10%.

15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens FEDERATED HERMES, INC.'s linked filing trail.
Comparable ownership Top 5
FEDERATED HERMES, INC. 10%
TYBOURNE CAPITAL MANAGEMENT (HK) LTD 10%
MPM BioImpact LLC 7.2%
ORBIMED ADVISORS LLC 6.2%
BlackRock, Inc. 5.9%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
FEDERATED HERMES, INC.
13F 13D/G
Company
10%
from 13D/G
$45,726,864
1,765,516 shares
31 Mar 2026
TYBOURNE CAPITAL MANAGEMENT (HK) LTD
13D/G
10%
$13,378,307
1,268,086 shares
+$6,618,184 30 Jun 2025
MPM BioImpact LLC
13F 13D/G
Company
7.2%
from 13D/G
$25,917,664
1,000,682 shares
31 Mar 2026
ORBIMED ADVISORS LLC
13D/G 13F
Company
6.2%
$55,810,918
1,264,980 shares
+$33,309,718 30 Jun 2026
BlackRock, Inc.
13D/G 13F
Company
5.9%
$25,598,430
1,204,632 shares
$0 30 Jun 2026
Affinity Asset Advisors, LLC
13D/G 13F
Company
5.6%
$50,534,651
1,145,391 shares
+$13,696,039 30 Jun 2026
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q2 2026

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions
85
Shares
20,362,406
Rows available
85
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q2 2026 vs Q3 2025 Across Filers

Q3 2025 holders
42
Q2 2026 holders
85
Holder diff
43
Investor Q3 2025 Shares Q2 2026 Shares Share Diff Share Chg % Q3 2025 value Q2 2026 value Value change Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .